XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Operations and Comprehensive Income/(Loss) (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Revenue:        
Revenue $ 5,650 $ 646 $ 6,273 $ 646
Operating expenses:        
Cost of sales 149   149  
Research and development 87,733 93,207 267,688 249,584
Cost of research collaboration     50,000  
General and administrative 45,763 36,991 135,309 94,909
Total operating expenses: 133,645 130,198 453,146 344,493
Net operating loss (127,995) (129,552) (446,873) (343,847)
Loss on conversion of debt (61,102)   (100,589)  
(Loss)/gain from remeasurement of development derivative liability (4,219) 2,697 (42,483) (62,939)
Interest income 144 670 381 3,970
Interest expense (2,282) (9,499) (10,223) (20,327)
Other (expense)/income, net (117) (16) 1,366 4
Net loss (195,571) (135,700) (598,421) (423,139)
Other comprehensive (loss)/gain:        
Unrealized (loss)/gain on marketable securities (25) (430) 19 122
Foreign currency loss (156) (1,658) (1,912) (1,727)
Total other comprehensive loss (181) (2,088) (1,893) (1,605)
Comprehensive loss, net of tax $ (195,752) $ (137,788) $ (600,314) $ (424,744)
Net loss per common share, basic and diluted $ (2.28) $ (1.79) $ (7.31) $ (5.65)
Weighted-average number of common shares used in net loss per common share, basic and diluted 85,661 75,628 81,846 74,925
Product [Member]        
Revenue:        
Revenue $ 5,314 $ 0 $ 5,937 $ 0
Licensing and other revenue [Member]        
Revenue:        
Revenue $ 336 $ 646 $ 336 $ 646